Clearside Biomedical (CLSD) Price & Analysis

Q: What was Clearside Biomedical’s price range in the past 12 months?

Clearside Biomedical lowest stock price was $0.31 and its highest was $17.10 in the past 12 months.

Q: What is Clearside Biomedical’s market cap?

Clearside Biomedical’s market cap is $19.37M.

Q: When is Clearside Biomedical’s upcoming earnings report date?

Clearside Biomedical’s upcoming earnings report date is Mar 05, 2026 which is in 72 days.

Q: How were Clearside Biomedical’s earnings last quarter?

Clearside Biomedical released its earnings results on Nov 18, 2025. The company reported -$17.1 earnings per share for the quarter, missing the consensus estimate of -$0.618 by -$16.482.

Q: Is Clearside Biomedical overvalued?

According to Wall Street analysts Clearside Biomedical’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Clearside Biomedical pay dividends?

Clearside Biomedical does not currently pay dividends.

Q: What is Clearside Biomedical’s EPS estimate?

Clearside Biomedical’s EPS estimate is -0.6.

Q: How many shares outstanding does Clearside Biomedical have?

Clearside Biomedical has 5,234,021 shares outstanding.

Q: What happened to Clearside Biomedical’s price movement after its last earnings report?

Clearside Biomedical reported an EPS of -$17.1 in its last earnings report, missing expectations of -$0.618. Following the earnings report the stock price went down -8.084%.

Q: Which hedge fund is a major shareholder of Clearside Biomedical?

Currently, no hedge funds are holding shares in CLSD

Compare

1,073 Followers

CLSD Stock Chart & Stats

$0.95

<$0.01(0.46%)

At close: Jan 08 4:00 PM EST

$0.95

<$0.01(0.46%)

Day’s Range― - ―

52-Week Range$0.31 - $17.10

Previous CloseN/A

Volume106.43K

Average Volume (3M)64.39K

Market Cap

$19.37M

Enterprise Value$109.13M

Total Cash (Recent Filing)$6.80M

Total Debt (Recent Filing)$446.00K

Price to Earnings (P/E)―

Beta1.08

Next Earnings

Mar 05, 2026

EPS Estimate

-0.6

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-17.10

Shares Outstanding5,234,021

10 Day Avg. Volume36,098

30 Day Avg. Volume64,393

Financial Highlights & Ratios

PEG Ratio0.18

Price to Book (P/B)-1.80

Price to Sales (P/S)42.14

P/FCF Ratio-2.73

Enterprise Value/Market Cap5.64

Enterprise Value/Revenue32.78

Enterprise Value/Gross Profit38.32

Enterprise Value/Ebitda-7.60

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Bears Say

Operational ChangesAll Clearside Biomedical employees and management have transitioned to consultants, indicating a reduction in workforce.

Program Development ChallengesThe company reported difficulties in securing funding or a partnership needed to advance its CLS-AX program into phase 3 development.

Strategic AlternativesCLSD announced it is taking the next steps to maximize shareholder value by hiring an investment bank to explore strategic alternatives to advance its programs.

Clearside Biomedical News

Two new option listings and one option delisting on December 1st

New option listings for December 1st include CLSDQ Stock (CLSDQ) and Cresud SA (CRESY). Option delistings effective December...

22d ago

CLSD

Why Is Clearside Biomedical Stock (CLSD) Down Today?

Clearside Biomedical stock dove on Monday after the biopharmaceutical company’s voluntary Chapter 11 filing. ...

29d ago

CLSD

Clearside Biomedical to pursue sale of business via Chapter 11 process

Clearside Biomedical (CLSD) filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code in the U.S....

29d ago

CLSD

Clearside Biomedical Faces Delisting After Bankruptcy Filing

The latest update is out from Clearside Biomedical ( ($CLSD) ). On November 23, 2025, Clearside Biomedical filed...

28d ago

CLSD

Clearside Biomedical Faces Uncertainty Amid Funding Challenges and Strategic Alternatives

Needham analyst Serge Belanger has maintained their neutral stance on CLSD stock, giving a Hold rating on November...

1M ago

CLSD

CLSD Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Clearside Biomedical Inc (CLSD) is scheduled to report 3rd quarter earnings on 11/18/2025. Regarding Q3 estimates, Wall Street...

1M ago

CLSD

Clearside Biomedical Inc. Explores Strategic Alternatives

Clearside Biomedical Inc ( ($CLSD) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

CLSD

VTI ETF Daily Report: 11/10/2025

The Vanguard Total Stock Market ETF ($VTI) tracks the performance of the entire U.S. equity market. VTI ETF is...

1M ago

LVO

VTI

VTI ETF Daily Update: What Investors Need to Know – 11/6/2025

How is the VTI ETF faring? Vanguard Total Stock Market ETF ($VTI) is an all-in-one fund that lets...

2M ago

LVO

VTI

VTI ETF Daily Update: What Investors Need to Know – 11/5/2025

How is the VTI ETF faring? Vanguard Total Stock Market ETF ($VTI) is an all-in-one fund that lets...

2M ago

LVO

VTI

VTI ETF Daily Update, 10/27/2025

How is VTI ETF faring? Vanguard Total Stock Market ETF ($VTI) is an all-in-one fund that lets investors...

2M ago

LVO

VTI

VTI ETF Daily Update, 10/24/2025

How is VTI ETF faring? Vanguard Total Stock Market ETF ($VTI) is an all-in-one fund that lets investors...

2M ago

IBM

LVO

Clearside Biomedical trading halted, news pending

19:50 EDT Clearside Biomedical (CLSD) trading halted, news pending Published first on TheFly – the ultimate source for...

3M ago

CLSD

Clearside Biomedical announces approval of XIPERE in Canada

Clearside Biomedical (CLSD) announced that Health Canada has granted approval for XIPERE for suprachoroidal use in the treatment...

5M ago

CLSD

CLSD FAQ

What was Clearside Biomedical’s price range in the past 12 months?

Clearside Biomedical lowest stock price was $0.31 and its highest was $17.10 in the past 12 months.

What is Clearside Biomedical’s market cap?

Clearside Biomedical’s market cap is $19.37M.

When is Clearside Biomedical’s upcoming earnings report date?

Clearside Biomedical’s upcoming earnings report date is Mar 05, 2026 which is in 72 days.

How were Clearside Biomedical’s earnings last quarter?

Clearside Biomedical released its earnings results on Nov 18, 2025. The company reported -$17.1 earnings per share for the quarter, missing the consensus estimate of -$0.618 by -$16.482.

Is Clearside Biomedical overvalued?

According to Wall Street analysts Clearside Biomedical’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Clearside Biomedical pay dividends?

Clearside Biomedical does not currently pay dividends.

What is Clearside Biomedical’s EPS estimate?

Clearside Biomedical’s EPS estimate is -0.6.

How many shares outstanding does Clearside Biomedical have?

Clearside Biomedical has 5,234,021 shares outstanding.

What happened to Clearside Biomedical’s price movement after its last earnings report?

Clearside Biomedical reported an EPS of -$17.1 in its last earnings report, missing expectations of -$0.618. Following the earnings report the stock price went down -8.084%.

Which hedge fund is a major shareholder of Clearside Biomedical?

Currently, no hedge funds are holding shares in CLSD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Clearside Biomedical

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Clearside Biomedical (CLSD) Earnings & Revenues

Historic Earnings Reports

CLSD Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","17":"$17","-1":"-$1","3.5":"$3.5","12.5":"$12.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,3.5,8,12.5,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.43,0.39692307692307693,0.3638461538461538,0.33076923076923076,0.2976923076923077,0.26461538461538464,0.23153846153846155,0.19846153846153847,0.1653846153846154,0.13230769230769235,0.09923076923076929,0.06615384615384617,0.033076923076923115,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.43,0.39692307692307693,0.3638461538461538,0.33076923076923076,0.2976923076923077,0.26461538461538464,0.23153846153846155,0.19846153846153847,0.1653846153846154,0.13230769230769235,0.09923076923076929,0.06615384615384617,0.033076923076923115,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.43,0.39692307692307693,0.3638461538461538,0.33076923076923076,0.2976923076923077,0.26461538461538464,0.23153846153846155,0.19846153846153847,0.1653846153846154,0.13230769230769235,0.09923076923076929,0.06615384615384617,0.033076923076923115,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.35,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.25,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.95,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.61,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.78,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.89,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.76,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.09,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.18,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.07,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.43,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >